News
Coupled with the invalidation of 10x Genomics’ 10,155,981 patent last year, Parse has now invalidated all claims that 10x Genomics asserts against Parse products, further reinforcing Parse’s ...
10x Genomics (NASDAQ:TXG) announced on Monday that its ATAC-Seq patents were found valid and infringed in its patent litigation with Parse Biosciences. On February 25, 2025, a consent agreement ...
PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences ...
The Tuesday decision dealt a setback to 10x Genomics, ... Parse Biosciences co-founder and CEO Alex Rosenberg spun the company out of the University of Washington in 2018.
10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February ...
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and ...
10x Genomics (NASDAQ:TXG) announced on Monday that its ATAC-Seq patents were found valid and infringed in its patent litigation with Parse Biosciences. On February 25, 2025, a consent agreement ...
PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences ...
PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results